Rely on NovoSeven® RT—it is proven effective to treat GT at home. Clinical trials show it controls bleeds in a majority of GT-related bleeds, and in surgical procedures.
An effective therapy option for you.
NovoSeven® RT is the only recombinant treatment indicated for Glanzmann's thrombasthenia (GT) when platelets don't work.
Controls bleeds, wherever and whenever they happen.
Bleed control seen in clinical trialsa
Real-world efficacy in children (post-clinical trials).
- 94% bleed control in patients 0 to 12 years
- 100% bleed control in patients >12 to 16 years
aEffectiveness seen in a prospective, observational, multinational study (from an analysis of published cases and people who took part in trials and registries).
bNovoSeven® RT only and NovoSeven® RT with platelets and/or antifibrinolytics.
Goes where you go.
NovoSeven® RT is portable and travel ready, with compact packaging that’s easy to pack in a carry-on or backpack. And because it’s room temperature stable up to 77°F, there's no need to refrigerate.c
cNovoSeven® RT should be stored between 36°F and 77°F.
For complete storage information, please see Prescribing Information.
Quick to mix.d
NovoSeven® RT with MixPro® makes mixing a dose as easy as attach, twist, and mix. The prefilled syringe saves time—there are no extra steps to fill a syringe with diluent.
After mixing, NovoSeven® RT may be stored at room temperature in the vial for up to 3 hours—so you can mix a dose, then take it along to infuse later.
dCompared with mixing using histidine vials.
Fast to infuse.
NovoSeven® RT provides low infusion volume, so infusing takes 2 to 5 minutes.e NovoSeven® RT is given as an intravenous (IV) bolus injection.
eAdminister as a slow bolus injection over 2 to 5 minutes, depending on the dose administered.
Safety supported by clinical experience.
NovoSeven® RT is a recombinant product, meaning it is made without human blood or plasma. This minimizes the possibility of viral contamination. NovoSeven® RT is the only recombinant therapy indicated for GT.f And its safety is supported by real-world evidence, with a <0.2% rate of unexpected blood clots reported.
Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.
fIn patients with refractoriness to platelet transfusions, with or without antibodies to platelets.
What if I need surgery or a procedure?
We understand that you have concerns about controlling bleeds if you ever need surgery or a procedure. The good news is that NovoSeven® RT prevents bleeds during and after surgery and procedures in people with GT.
Talk to your doctor for more information on the surgical use of NovoSeven® RT.